Startacus
Join Now! /

Manus secures funding to support launch of its Parkinson's Pen

Startacus RSS

by Startacus Admin

Prof Richard Walker - clinical lead advisor to Manus - with patient

Medtech company Manus raises £1.2m to help with the roll-out of its NeuroMotor pen designed for use in the diagnosis and monitoring of neuromotor impairments

manus imageInnovative Edinburgh medtech company Manus Neurodynamica Limited (“Manus”), has just secured £1.2M in funding to support the launch of its digital pen which provides an early warning of Parkinson's disease and other neurological conditions.

The NeuroMotor Pen employs sensors linked with analytical software which analyses the slightest limb and hand movements to help doctors assess whether a patient has early signs of Parkinson's or other neurological conditions. As well as providing a quick, inexpensive, non-invasive and objective aid to diagnosis, the CE-marked product also helps with the ongoing monitoring of those conditions.

Dr Rutger Zietsma, Chief Executive Officer, Manus Neurodynamica.Dr Rutger Zietsma, CEO Manus Neurodynamica, said: “2021 looks set to be an extremely busy year for Manus. Having spent more than 10 years developing, trialing and refining our first product, we can finally look forward to seeing our NeuroMotor Pens implemented more broadly and making a real difference to the lives of people living with Parkinson’s and other neurological conditions.

Through faster and simpler diagnoses and objective patient monitoring with digital record keeping, we can help streamline the pathway and deliver more successful treatment outcomes for the fastest growing neurological condition in the world.”

manus neuroInvestors in this funding round included the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, profit with purpose investor SIS Ventures and Old College Capital, the University of Edinburgh’s venture fund.

Rob Halliday, Fund Manager, SIS Ventures said: “Manus is one of Scotland’s most promising early stage medtech companies, with the potential to make a huge impact. With its disruptive technology, mission-led approach, and ambitious management team, Manus is exactly the kind of business we look to invest in at SIS Ventures. Working along with the other investors, we’re very pleased to support Rutger and his team through their next phase of growth and impact creation.”

The funding will enable Manus to roll-out its NeuroMotor PenTM later this year, while also progressing work to secure regulatory approval to start selling in the US.

Exciting times ahead for this innovative startup...  

 


Subscribe to our newsletter

If you would like to receive our startup themed newsletter, full of the latest startup opportunities, events, news, stories, tips and advice, then sign up here.
Startacus RSS
Business DealsSubmit Your Startup
Win TicketsNetwork and Collaborate
Our Latest Features



Published on: 26th January 2021

If you would like to enable commenting via your Startacus account, please enable Disqus functionality in your Account Settings.


Create an Idea!View Other Ideas, Projects or Startups
Why not Sign Up?
Create Projects
Edit Projects
Self Interviews
Self Starter of the Year
Product Giveaways
Subscribe to our Newsletter
Startacus
Check us out at our Google+ page!